Subject(s)
Arrhythmias, Cardiac , COVID-19 Drug Treatment , COVID-19 , Chemoprevention , Hydroxychloroquine , Antimalarials/administration & dosage , Antimalarials/adverse effects , Arrhythmias, Cardiac/chemically induced , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/prevention & control , COVID-19/epidemiology , COVID-19/prevention & control , Chemoprevention/adverse effects , Chemoprevention/methods , Humans , Hydroxychloroquine/administration & dosage , Hydroxychloroquine/adverse effects , Randomized Controlled Trials as Topic , Risk Assessment , SARS-CoV-2ABSTRACT
In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk-benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.